KR101413785B1 - Ｄｉｃｋｋｏｐｆ-1 및/또는 -4의 항체에 대한 조성물 및 사용 방법 - Google Patents

Ｄｉｃｋｋｏｐｆ-1 및/또는 -4의 항체에 대한 조성물 및 사용 방법 Download PDF

Info

Publication number
KR101413785B1
KR101413785B1 KR1020087019725A KR20087019725A KR101413785B1 KR 101413785 B1 KR101413785 B1 KR 101413785B1 KR 1020087019725 A KR1020087019725 A KR 1020087019725A KR 20087019725 A KR20087019725 A KR 20087019725A KR 101413785 B1 KR101413785 B1 KR 101413785B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
dkk1
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087019725A
Other languages
English (en)
Korean (ko)
Other versions
KR20080085908A (ko
Inventor
제닌 셜록
펭 콩
마크 피쉬맨
세스 에텐버그
미하엘 발드로프
마리엘 동조
스테파니 울링거
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20080085908A publication Critical patent/KR20080085908A/ko
Application granted granted Critical
Publication of KR101413785B1 publication Critical patent/KR101413785B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
KR1020087019725A 2006-01-13 2007-01-12 Ｄｉｃｋｋｏｐｆ-1 및/또는 -4의 항체에 대한 조성물 및 사용 방법 Expired - Fee Related KR101413785B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75921606P 2006-01-13 2006-01-13
US60/759,216 2006-01-13
PCT/US2007/000777 WO2007084344A2 (en) 2006-01-13 2007-01-12 Compositions and methods of use for antibodies of dickkopf-1 and/or -4

Publications (2)

Publication Number Publication Date
KR20080085908A KR20080085908A (ko) 2008-09-24
KR101413785B1 true KR101413785B1 (ko) 2014-07-09

Family

ID=38288117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087019725A Expired - Fee Related KR101413785B1 (ko) 2006-01-13 2007-01-12 Ｄｉｃｋｋｏｐｆ-1 및/또는 -4의 항체에 대한 조성물 및 사용 방법

Country Status (30)

Country Link
US (3) US8673306B2 (enExample)
EP (1) EP1976594B1 (enExample)
JP (2) JP5552233B2 (enExample)
KR (1) KR101413785B1 (enExample)
CN (1) CN101400406B (enExample)
AR (1) AR060017A1 (enExample)
AU (1) AU2007207787B2 (enExample)
BR (1) BRPI0706524A2 (enExample)
CA (1) CA2636579A1 (enExample)
CR (1) CR10128A (enExample)
CU (1) CU23871B1 (enExample)
EA (1) EA015538B1 (enExample)
EC (1) ECSP088618A (enExample)
GE (1) GEP20125476B (enExample)
HN (1) HN2008001104A (enExample)
IL (1) IL192631A (enExample)
MA (1) MA30158B1 (enExample)
ME (2) MEP1308A (enExample)
MY (1) MY153573A (enExample)
NO (1) NO20083477L (enExample)
NZ (1) NZ569555A (enExample)
PE (2) PE20120816A1 (enExample)
SG (1) SG169327A1 (enExample)
SM (1) SMP200800042B (enExample)
SV (1) SV2008002980A (enExample)
TN (1) TNSN08297A1 (enExample)
TW (1) TWI432450B (enExample)
UA (1) UA101944C2 (enExample)
WO (1) WO2007084344A2 (enExample)
ZA (1) ZA200805743B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8450274B2 (en) 2006-05-24 2013-05-28 Theragenetex Co., Ltd. DKK2 protein and use thereof
KR101218806B1 (ko) * 2010-04-21 2013-01-09 주식회사 테라젠이텍스 Ｄｋｋ2 단백질 및 그의 용도
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP5320730B2 (ja) * 2007-12-26 2013-10-23 Ｊｎｃ株式会社 発光基質水溶液およびその製造方法
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
US20120052070A1 (en) * 2009-05-07 2012-03-01 Novartis Ag Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
NZ596274A (en) 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
WO2010130832A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US20120208208A1 (en) * 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
TWI636993B (zh) * 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
CN103649118A (zh) 2011-03-01 2014-03-19 安进公司 双特异性结合剂
CN103487581A (zh) * 2012-06-08 2014-01-01 上海市肿瘤研究所 血清dkk1在制备甲胎蛋白阴性肝细胞癌的诊断试剂中的用途
CN103472226A (zh) * 2012-06-08 2013-12-25 上海市肿瘤研究所 血清dkk1在制备早期肝细胞癌或小肝细胞癌的诊断试剂中的用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
CN103083686B (zh) * 2013-02-18 2014-09-10 上海交通大学医学院附属仁济医院 Dkk4基因及其编码蛋白在制备药物中的应用
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CN106659912B (zh) * 2014-07-03 2021-11-30 耶鲁大学 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
DE102016206820B4 (de) 2015-04-22 2017-07-27 BSH Hausgeräte GmbH Weiterentwicklung eines Induktionswasserkochers, einer Kaffeemaschine und einer Suppenmaschine
IL294679B2 (en) 2015-08-07 2023-10-01 Alx Oncology Inc Structures with a SIRP-alpha site or its variant
CN105203773A (zh) * 2015-09-28 2015-12-30 成都博奥新景医学科技有限公司 一种人Dickkopf-1蛋白（DKK-1）定量检测试剂盒
RU2018119317A (ru) * 2015-10-28 2019-12-04 Йейл Юниверсити Гуманизированное антитело к dkk2 и его применение
RU2656160C2 (ru) * 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
WO2018208108A1 (ko) * 2017-05-10 2018-11-15 주식회사 굳티셀 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도
EP3913055A4 (en) * 2019-01-15 2023-09-27 Bioneer Corporation DOUBLE STRANDED OLIGONUCLEOTIDE TARGETED AGAINST DKK1 GENE, CONSTRUCT AND COMPOSITION CONTAINING SAME FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH THEREFOR
AU2020216494A1 (en) 2019-02-01 2021-08-12 Board Of Regents, The University Of Texas System Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof
CN119700933A (zh) 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CN112180094A (zh) * 2019-07-04 2021-01-05 上海东慈生物科技有限公司 Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
CN111632147A (zh) * 2020-06-07 2020-09-08 重庆医科大学 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
US20250270304A1 (en) * 2020-12-23 2025-08-28 Phenomic Ai Anti-activin antibodies and methods of using the same
AU2022273727A1 (en) 2021-05-13 2023-11-09 ALX Oncology Inc. Combination therapies for treating cancer
CN117916377A (zh) * 2021-09-26 2024-04-19 安沛治疗有限公司 针对dkk1的适体及其用途
US20250122271A1 (en) * 2022-01-28 2025-04-17 Shanghai Junshi Biosciences Co., Ltd. Anti-dkk1 antibody, pharmaceutical composition thereof, and use thereof
WO2024216064A1 (en) * 2023-04-14 2024-10-17 Twist Bioscience Corporation Compositions and methods related to dkk1 binders
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597710A (en) 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CA2288430C (en) 1997-04-16 2013-04-09 Millennium Biotherapeutics, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AU5233599A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Ddkh-3 nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
US6951921B2 (en) 1998-09-01 2005-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
MX337162B (es) 2001-01-05 2016-02-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
US20030165501A1 (en) * 2001-02-16 2003-09-04 Genentech, Inc. Treatment involving Dkk-1 or antagonists thereof
ATE484522T1 (de) * 2001-04-24 2010-10-15 Bayer Corp Menschliche antikörper gegen timp-1
CA2466483A1 (en) 2001-11-07 2003-07-03 John D. Shaughnessy Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP1567663A4 (en) 2002-12-05 2006-04-19 Univ Arkansas MOLECULAR DETERMINANTS OF MULTIPLE MYELOMA AND ITS USE
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
EP2336177A1 (en) * 2004-08-04 2011-06-22 Amgen, Inc Antibodies to DKK-1
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101146909A (zh) * 2005-03-25 2008-03-19 格黎卡特生物技术股份公司 针对MCSP的并且具有增加的Fc受体结合亲和性和效应子功能的抗原结合分子
CA2627075A1 (en) * 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1

Also Published As

Publication number Publication date
EA200801679A1 (ru) 2009-02-27
US8673306B2 (en) 2014-03-18
WO2007084344A2 (en) 2007-07-26
ECSP088618A (es) 2008-08-29
US20140170147A1 (en) 2014-06-19
GEP20125476B (en) 2012-04-25
ZA200805743B (en) 2009-08-26
JP2013099334A (ja) 2013-05-23
SG169327A1 (en) 2011-03-30
CR10128A (es) 2008-08-25
CN101400406B (zh) 2014-01-29
JP5552233B2 (ja) 2014-07-16
AU2007207787B2 (en) 2011-03-17
PE20071239A1 (es) 2008-02-12
AR060017A1 (es) 2008-05-21
TW200804417A (en) 2008-01-16
MA30158B1 (fr) 2009-01-02
MEP1308A (xx) 2010-02-10
EP1976594A2 (en) 2008-10-08
HN2008001104A (es) 2011-06-08
NO20083477L (no) 2008-10-13
UA101944C2 (ru) 2013-05-27
BRPI0706524A2 (pt) 2011-03-29
IL192631A0 (en) 2011-08-01
JP2009523421A (ja) 2009-06-25
SMAP200800042A (it) 2008-07-30
CN101400406A (zh) 2009-04-01
SMP200800042B (it) 2009-07-14
NZ569555A (en) 2011-12-22
ME00010B (me) 2010-06-10
MY153573A (en) 2015-02-27
SV2008002980A (es) 2010-05-21
WO2007084344A3 (en) 2008-02-14
KR20080085908A (ko) 2008-09-24
TWI432450B (zh) 2014-04-01
US9296813B2 (en) 2016-03-29
PE20120816A1 (es) 2012-08-01
EP1976594B1 (en) 2015-05-06
TNSN08297A1 (en) 2009-12-29
AU2007207787A1 (en) 2007-07-26
EA015538B1 (ru) 2011-08-30
HK1121420A1 (en) 2009-04-24
CU20080133A7 (es) 2012-06-21
CA2636579A1 (en) 2007-07-26
US20120023600A1 (en) 2012-01-26
US20140341901A1 (en) 2014-11-20
IL192631A (en) 2015-06-30
CU23871B1 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
KR101413785B1 (ko) Ｄｉｃｋｋｏｐｆ-1 및/또는 -4의 항체에 대한 조성물 및 사용 방법
CN101415730B (zh) c-Met抗体的组合物和使用方法
KR101836501B1 (ko) 근육 성장을 증가시키기 위한 조성물 및 방법
KR20120117621A (ko) 딕코프－１ 또는 딕코프－４ 또는 둘 모두에 대한 결합 분자에 대한 조성물 및 사용 방법
KR20120088551A (ko) 보체 단백질 ｃ３ｂ를 표적화하는 항체를 위한 조성물 및 방법
KR20180107151A (ko) Tgf베타 2 항체
KR20140003467A (ko) 항il-18 항체 및 그의 용도
MX2008008948A (es) Composiciones y metodos de uso para anticuerpos de dickkopf-1 y/o -4
HK1121420B (en) Compositions and methods of use of antibodies against dickkopf-1 and dickkopf-4

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170625

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170625

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000